logo
askST: What is pre-authorisation, and can insurers refuse to give it?

askST: What is pre-authorisation, and can insurers refuse to give it?

Yahoo2 days ago

SINGAPORE - Insurance group Great Eastern (GE) announced on June 17 that it had temporarily stopped issuing pre-authorisation certificates for policyholders admitted to Mount Elizabeth hospitals.
Mount Elizabeth and Mount Elizabeth Novena hospitals had higher costs than other private hospitals, GE said, adding that its move was aimed at 'prioritising facilities that deliver the same high-quality care with greater cost transparency and cost-effectiveness'.
The decision took both the hospitals and GE policyholders by surprise.
The Straits Times looks at how withholding pre-authorisation certificates may affect healthcare and hospitalisation coverage of policyholders.
Some health insurance plans require the doctor of its policyholder to request a pre-authorisation certificate before doing specific procedures.
A pre-authorisation certificate effectively confirms that the insurer has approved the medical treatment, including the costs, before the treatment begins.
Without getting pre-approval, some or all of the bill may not be covered by insurance, leaving the patient to pay for it himself.
This process helps the insurer assess whether a treatment recommended by the doctor is medically necessary, and at a reasonable cost.
For the policyholder, it ensures that the treatment is covered under the plan. It also keeps out-of-pocket expenses in check, allowing the insurer to settle the medical bill directly with the hospital.
Through the pre-authorisation process, the insurer helps ensure the policyholder receives cost-effective treatments.
Non-panel specialists and government hospitals require a letter of guarantee (LOG).
It provides assurance of payment to hospitals on behalf of patients for the portion of their medical bills covered by insurance, reduces the upfront cash deposit the hospital requires, and makes healthcare more accessible and affordable for patients.
In Singapore, patients may need both the LOG and the pre-authorisation certificate before undergoing surgery.
To apply for both, the patient needs to consult his doctor, who will then submit a pre-authorisation request to the insurer.
If approved, the insurer may also issue an LOG at the patient's request, assuring direct payment to the hospital for covered expenses.
The patient may also need to submit additional documents and forms, depending on the insurer and the specific treatment.
The pre-authorisation certificate is the insurer's permit for a specific surgery or procedure, while the LOG assures the payment for the hospitalisation is covered by insurance.
The pre-authorisation provides clarity on coverage and potential costs before the policyholder undergoes treatment, allowing the patient to plan his healthcare expenses accordingly.
Without it, patients would have to fork out money from their own pocket, and file a claim later – risking partial reimbursement or outright rejection.
The LOG reduces upfront payment to the hospital, easing admission and surgeries, and can be generated instantly for selected public hospitals and institutions.
Insurers can withhold pre-authorisation, and the reasons for doing so are:
The planned treatment or procedure is not included in the policyholder's coverage;
The insurer determines that the treatment is not medically necessary based on its review;
The estimated costs are significantly higher than what the insurer deems reasonable;
The insurer needs more information from the doctor or patient to assess the request;
The policy requires treatment at a specific panel of doctors or hospitals; and
In emergency situations where the pre-authorisation is waived, the insurer may deny coverage later if the treatment is deemed not necessary.
However, insurers are encouraged by the Life Insurance Association to clearly communicate the reasons for withholding pre-authorisation to both the policyholder and the healthcare provider.
This is because policyholders have the right to appeal against the insurer's decision to withhold pre-authorisation if they disagree with the insurer's assessment.
Source: The Straits Times © SPH Media Limited. Permission required for reproduction
Discover how to enjoy other premium articles here

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biotech industry faces off: US vs. China
Biotech industry faces off: US vs. China

Yahoo

timean hour ago

  • Yahoo

Biotech industry faces off: US vs. China

China has become a significant player in the biotech space, potentially threatening the lead the US holds. EY Americas industry markets leader for health sciences and wellness Arda Ural sits down with Josh Lipton and Yahoo Finance Senior Reporter Anjalee Khemlani to discuss the dynamics between the US and China in the biotech industry. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here According to a recent report from the Harvard Belfer Center for Science and International Affairs, China has the most immediate opportunity to overtake the United States in biotechnology. For more, let's welcome in Arta Rawi America's industry markets leader and Health Sciences and wellness, as well as Yahoo Finance's very own Anjali Camlani. Welcome to you both. All right, I'll start with you. Uh, maybe it's just a big question, big picture question. Does the US have the investment power, in your opinion, to overtake China in biotech? Yeah, thanks for having me. Uh, the biotech is the innovation feeder to the big pharmaceuticals and it only uh nurtures well in an ecosystem. So to answer your question, what do you need in that ecosystem for that to nurture? Uh, investment capacity, which we have been having for the last, you know, decades, if you will, to kind of keep investing in that innovation to move on. NIH has been probably the world's largest VC over $40 billion in non-dilute funding into the entrepreneurial startups. Then you have talent who has been, you know, coming all these top universities and MDs and PhDs who are dedicated to advance it. And then you need this technology transfer system so that those intellectual property translate into a startup. And then with that investment capacity, it keeps growing and then through testing and going to the humans and then ultimately being developed for everyone's use. So, uh, yes, the US still has the capacity to invest, but it is not potentially the only game in town given the development coming from China. I'm curious, Arta, because we know, I know you've been tracking the deals and uh, we've seen the number of deals steadily increasing over the years. I saw, uh, one of the ones that you sent, which looks at the number of deals so far to date for 2025 is more than half of what we saw in 2024. So we can expect that to really outpace 2024. What does that mean though? Because I know that some of the deals that are happening are more, um, what you would call licensing deals, right? It's not necessarily that this money is going to from scratch investment and innovation, but it's more stuff that has already happened and is built up. Talk to me about that and why that matters. I mean, first of all, the numbers are pretty compelling. A couple years ago, we had pretty much like no deals under a billion dollars in 2016. And as of last year, there were $30 billion worth of licensing deals from Chinese assets into the US, and 2025 is a very strong start, so they're definitely going to beat that number. So the reason why this is happening is in 2015, Chinese Communist Party put a priority of investing in biotech and that was a priority sectors. And it was 10 years ago, and that 10 years of journey started to play out for their benefit because China historically has been known for this active product ingredients and excipients, which is like the chemicals that pharmaceuticals were using to make small molecule products. And that journey now is taking them to upstream to more advanced innovation. Probably we still have not seen a first in class, but clearly they are going for best in class, like those are the shots on goal if you are seeing more and more. Well, that's why, that would be my question because I know that we've seen sort of they're doing copycats or metoos in terms of the type of innovation coming out of China. Um, do we expect that they have the wherewithal to outdo the US then in that sense, in terms of coming up with the next blockbuster for the entire world? I mean, there are a couple examples, early examples that some of the Chinese based assets actually head-to-head comparisons, you know, beat or exceed, at least match the efficacy and safety profile of some of the Western developed compounds. But this is also a journey as the audio question. So what is it, what do they need more to get there? So they have the talent. I mean a lot of Western educated MDs and PhDs went back to China working on that. The government itself as a part of prioritization program have been investing in it. So then the question is, do they have an exit strategy for those entrepreneurs? And that I think is where they are lacking because there's no like an IPO market that is comparable to the Western standards. There's no like an M&A exit until recently. I think that's where the weakness kind of may be the opportunity for them to come up. But the deals we were talking about, they're because of the intellectual property concerns, because of the concerns of reliability and trust in the data because, you know, there's no such institution in the world like FDA that everyone trusts and hopefully continue to trust. And for that reason, the deals seem to be more asset purchases. So I'm not taking a risk by operating in China, but I'm buying the asset and in a licensing deal, and I'll continue to develop it, especially if you can make this cheaper and faster in China, which has been their competitive advantage over the Western companies, then you bring that into a human fast and then the human testing can be done, validations can be done in the more Western setting. I think that can be a winning formula for the industry. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Health Insurers Take Major Accountability Step On Prior Authorization
Health Insurers Take Major Accountability Step On Prior Authorization

Forbes

time4 hours ago

  • Forbes

Health Insurers Take Major Accountability Step On Prior Authorization

The nation's biggest health insurance companies are poised to ease prior authorization, the process ... More of insurers reviewing hospital admissions and medications. Details of the changes will be announced as early as Monday, June 23, 2025. getty The nation's biggest health insurance companies are poised to ease prior authorization, the process of insurers reviewing hospital admissions and medications. The policy change, expected to be announced as early as Monday by America's Health Insurance Plans, also known as AHIP, and the Chicago-based Blue Cross Blue Shield Association has been at the forefront of legislative efforts in Washington and state capitals across the country. The health insurers effort to improve accountability, transparency and customer support after an outpouring of public anger at the health insurance industry following the Dec. 4 UnitedHealthcare CEO shooting. Doctors complain prior authorization has delayed needed treatment and put patient health in jeopardy while wasting physician time to jump through hoops and adding to physician burnout. Over the past several years, prior authorization increasingly has become a concern for patient access to needed services, according to almost 30% of physicians responding to an American Medical Association survey in 2023. Health insurers involved in the effort say companies have agreed to streamline, simplify and reduce prior authorization, according to two health plans with knowledge of the changes. Neither AHIP nor the Blue Cross Blue Shield Association would comment when reached Friday afternoon. AHIP represents some of the biggest names in health insurance including CVS Health's Aetna, Centene, Cigna, Humana and Elevance Health. Blue Cross Blue Shield Association represents the nation's Blue Cross plans including Florida Blue and Health Care Service Corp., parent of Blue Cross and Blue Shield plans in five states. Sources close to the effort from participating plans say the insurers are committed to the changes in all health plans that they sell including commercial coverage, Medicare Advantage for seniors and Medicaid health plans that they administer for low-income Americans via contracts with states. The changes could benefit more than 250 million Americans. Further details weren't available. The effort is the latest and biggest so far among health insurers. Earlier this year, The Cigna Group announced a new multi-year effort to improve accountability. Cigna's announcement to launch 'actions to drive positive change for customers and patients' came just days after company chief executive David Cordani addressed analysts and investors on the industry's need to provide customers with more support and resources to navigate the healthcare system. 'In early December, we all witnessed the tragic murder of Brian Thompson, a leader at the UnitedHealth Group,' Cordani told analysts and investors on the company's fourth quarter and full year 2024 earnings call. 'The past several weeks have further challenged us to even more intensely listen to the public narrative about our industry. At The Cigna Group, we are further accelerating improvements in innovations to increase transparency, expand support and drive even greater accountability." Cigna was the first rival of UnitedHealth Group's UnitedHealthcare to roll out some reforms since the shooting in New York on the company's annual investor day. Thompson's death unleashed a barrage of scrutiny on health insurer denials of medical care and certain other business practices from social media trolls and industry critics including some in Congress who say they'd like to see reform.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store